Could a simple estrogen pill reveal hidden oxytocin deficiency?
NCT ID NCT07361263
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study is testing whether taking estrogen pills (estradiol valerate or ethinylestradiol) can safely trigger the release of oxytocin, a hormone important for social bonding and childbirth. Researchers will measure oxytocin levels in 28 healthy volunteers and patients with AVP deficiency (a condition affecting water balance). The goal is to develop a new diagnostic test for oxytocin deficiency, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- estradiol valerate and ethinylestradiol (estrogen pills)
- What this could lead to
- If successful, this could lead to a safe, simple diagnostic test for oxytocin deficiency, helping doctors identify and manage this condition more accurately.
- What could go wrong
- This is a very early, small study (28 participants) focused on measuring hormone levels, not treating disease. The approach may not reliably stimulate oxytocin or may cause side effects from estrogen.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 28 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2026
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 50 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Part 1 1. Adult healthy controls 2. No medication (including hormonal contraception) 3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months Part 2 1. Confirmed diagnosis of AVP-Deficiency 2. Age ≥ 18 years 3. Female patients (except post-menopausal): regular cycle (21-35 days of duration) in the last 6 months or in the case of hormone replacement therapy, with a 1-week pause from the respective treatment Exclusion Criteria: Part 1 1. Participation in a trial with investigational drugs within 30 days 2. BMI \>30 3. Age \>50 4. Illicit substance use (except for cannabis) during the last 30 days 5. Consumption of alcoholic beverages \>15 drinks/week 6. Tobacco smoking \>10 cigarettes/day 7. Pregnancy and breastfeeding 8. Hormonal contraception 9. Migraine with and without aura 10. Any cardiometabolic, cardiovascular, and hematological diseases (including deep vein thrombosis/pulmonary embolism and thrombophilia (DVT/PE)) 11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range 12. Diagnosed chronic kidney disease (CKD) \> grade III (GRF \< 30ml/min) Part 2 1. Participation in a trial with investigational drugs within 30 days 2. BMI \>30 3. Age \>50 4. Illicit substance use (except for cannabis) during the last 30 days 5. Consumption of alcoholic beverages \>15 drinks/week 6. Tobacco smoking \>10 cigarettes/day 7. Pregnancy and breastfeeding 8. Hormonal contraception 9. Migraine with and without aura 10. Any cardiometabolic, cardiovascular, and hematological diseases (including DVT/PE and Thrombophilia) 11. Active liver dysfunction or alanine aminotransferase (ALAT) or aspartate aminotransferase (ASAT) levels 2.5 times above the normal range 12. Diagnosed CKD \> grade III (GRF \< 30ml/min)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Avp deficiency are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University Hospital Basel
RECRUITINGBasel, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.